NEW DELHI: Dr Reddy s on Wednesday said that the supply of anti-Covid drug 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisation (DRDO) is expected to commence in mid-June.
In a statement, Hyderabad based Dr Reddy s said that the drug has not been launched in the market yet and people should be cautious of agents selling spurious or illegal products in the name of 2DG.
The anti-Covid therapeutic application of the drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the DRDO, in collaboration with Dr Reddy s Laboratories (DRL) in Hyderabad.
India News: Dr Reddy's on Wednesday said that the supply of anti-Covid drug 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisati
Panacea Biotec files suit against Sanofi for patent infringement
SECTIONS
Last Updated: May 17, 2021, 02:48 PM IST
Share
Synopsis The suit filed against Sanofi comes at the heels of Sanofi having received marketing approval for a Whole Cell Pertussis based Hexavalent vaccine by the Drugs Controller General (India), Panacea Biotec said in a regulatory filing.
Reuters
Panacea Biotec on Monday said it has filed a suit before the Delhi High Court seeking to restrain
Sanofi Healthcare India from marketing a fully liquid hexavalent vaccine. The national capital-based firm said a case has been filed in order to stop infringement of its patent for fully liquid whole cell pertussis based fully liquid Hexavalent vaccine EasySix.
India News: NEW DELHI: Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan on Monday released the first batch of anti-COVID drug 2-deoxy-D-g.
›Dr Reddy’s announces soft launch of Sputnik V in India, imported doses priced at Rs 948 and 5% GST
Dr Reddy’s announces soft launch of Sputnik V in India, imported doses priced at Rs 948 and 5% GST
SECTIONS
Dr Reddy’s announces soft launch of Sputnik V in India, imported doses priced at Rs 948 and 5% GSTBy
Share
Synopsis
Sputnik V was developed by Russia’s Gamaleya National Research Institute of Epidemiology and Microbiology with the backing of Russia’s sovereign fund Russian Direct Investment Fund. It was registered by the Russian health ministry as the world’s first Covid-19 vaccine based on the human adenoviral vector platform.